CancerResource—updated database of cancer-relevant proteins, mutations and interacting drugs

Abstract

Here, we present an updated version of CancerResource, freely available without registration at http://bioinformatics.charite.de/care. With upcoming information on target expression and mutations in patients’ tumors, the need for systems supporting decisions on individual therapy is growing. This knowledge is based on numerous, experimentally validated drug-target interactions and supporting analyses such as measuring changes in gene expression using microarrays and HTS-efforts on cell lines. To enable a better overview about similar drug-target data and supporting information, a series of novel information connections are established and made available as described in the following. CancerResource contains about 91 000 drug-target relations, more than 2000 cancer cell lines and drug sensitivity data for about 50 000 drugs. CancerResource enables the capability of uploading external expression and mutation data and comparing them to the database's cell lines. Target genes and compounds are projected onto cancer-related pathways to get a better overview about how drug-target interactions benefit the treatment of cancer. Features like cellular fingerprints comprising of mutations, expression values and drug-sensitivity data can promote the understanding of genotype to drug sensitivity associations. Ultimately, these profiles can also be used to determine the most effective drug treatment for a cancer cell line most similar to a patient's tumor cells.

Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics

“…These efforts have been partly facilitated by the knowledge of the genomics, transcriptomics, structures, interactions, biological systems and functional profiles of the therapeutic targets ( 7 – 10 ). In particular, a number of freely accessible databases complementarily provide comprehensive information about the therapeutic targets with additional information about the clinical trial drugs ( 11 – 13 ), biomarkers ( 11 ), molecular activity data ( 11 , 13 – 15 ), drug-binding sites ( 16 , 17 ) and target-affiliated biological pathways ( 11 , 18 ) of the targets, as well as the therapeutics ( 12 , 14 , 15 , 19 , 20 ) and ADME-Tox properties ( 12 ) of the targeted drugs.…”

Identification of Herb Pairs in Esophageal Cancer

“…We collected medical data from patients admitted to corresponding departments of our hospital and processed the data through preconditioning, filtering, rechecking, and excluding [18]. The data were then imported into DBMS7.0 [19].…”

Approach to Evaluate the Risk of Cancer for Different Number of Tumor Suppressor Genes in the Individual

“…The formation of a tumor becomes only a matter of time [5][6][7][8][9][10][11][12][13][14][15]. It is assumed that initially at birth the number of normally functioning suppressor genes may be different for different individuals and the number is equal to several units; in the modern literature dozens of such genes are described [16][17][18][19]. The question about the number of TSGs and their significance in the magnitude of the probability of cancer development is very disputable.…”